HIV and Peripheral Artery Disease: Acknowledging the Association

The role of human immunodeficiency virus (HIV) in the development of vascular disease (specifically peripheral artery disease) remains unclear. Is the virus per se the direct cause of this disease or is it a consequence of dyslipidemia, one of the adverse effects of antiretrovirals?

This study looked into the effect of HIV infection on peripheral artery disease after adjusting for all traditional risk factors in a large cohort of HIV+ patients and compared them with an uninfected population of similar baseline characteristics.

 

Of 91953 participant patients with a mean follow up of 9 years, researchers observed 7708 peripheral vascular events. Events rate per 1000 patient/year was higher among HIV+ patients (11.9% vs 9.9%).


Read also: MITRA-FR: Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation.


After adjusting for multiple demographic factors, traditional cardiovascular risk factors and other covariates, it was observed that HIV+ patients have higher incidence of peripheral vascular events, and the difference turned out to be significant (HR 1.19, CI 95%, 1.13 to 1.25).

 

Events risk was 1.5 fold higher in patients with viral load >500 copies/ml and nearly 2 fold higher in those with CD4 cell counts <200 cells/mm3, even though this had no effect in amputations rate. On the contrary, HIV+ patients with undetectable viral load and with CD4 cell counts ≥500/mm³ had identical events rate as uninfected patients.


Read also: OCT Provides Hints About the Physiopathology Behind Very Late Stent Thrombosis.


Mortality after vascular event was higher regardless HIV infection.

 

Conclusion

HIV infection was associated with a 19% increased risk of peripheral artery disease, beyond that explained by traditional risk factors. For patients with CD4 cell counts <200/mm³, risk resulted nearly 2-fold higher, whilst patients under control had similar risk as HIV negatives.

 

Original title: Association of Human Immunodeficiency Virus Infection and Risk of Peripheral Artery Disease.

Reference: Joshua A. Beckman et al. Circulation. 2018;138:255–265.

 

2018-09-10 HIV-y-vascular-periferica.full


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Therapeutic strategies in carotid free-floating thrombus: evidence and controversies

Carotid free-floating thrombus (cFFT) is a rare entity with a high embolic risk, associated with acute neurological events such as stroke or transient ischemic...

ACC 2026 | SirPAD Trial: Sirolimus-coated balloon angioplasty in infrainguinal arterial disease

Paclitaxel-coated balloons have demonstrated improved patency in peripheral arterial disease (PAD), although questions remain regarding safety and applicability across different vascular territories. In this...

ACC 2026 | HI-PEITHO: Catheter-directed strategy (EKOS) in intermediate-risk acute pulmonary embolism

The treatment of intermediate-risk pulmonary embolism (PE) continues to be an area of therapeutic uncertainty. The initial PEITHO study (2014) demonstrated a reduction in...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...